Equine herpesvirus-1 (EHV-1) infection is common in young horses throughout the world, resulting in respiratory disease, epidemic abortion, sporadic myelitis, or latent infections. To improve on conventional diagnostic tests for EHV-1, a real-time polymerase chain reaction (PCR) technique was developed, using primers and probes specific for the EHV-1 gB gene. Amplification efficiencies of 100% 6 5% were obtained for DNA isolated from a plasmid, infected peripheral blood mononuclear cells (PBMCs), and nasal secretions from infected ponies. The dynamic range of the assay was 8 log 10 dilutions, and the lower limit of detection was 6 DNA copies. Fifteen ponies, seronegative for EHV-1, were experimentally infected with EHV-1, and nasal samples were used to quantify shedding of virus by both virus isolation and real-time PCR analysis. Virus isolation identified nasal shedding of EHV-1 in 12/15 ponies on a total of 25 days; real-time PCR detected viral shedding in 15/15 ponies on 75 days. Viremia was quantified using PBMC DNA, subsequent to challenge infection in 3 additional ponies. Viremia was identified in 1/3 ponies on a single day by virus isolation; real-time PCR detected viremia in 3/3 ponies on 17 days. When real-time PCR was used to analyze PBMC DNA from 11 latently infected ponies (documented by nested PCR), EHV-1 was not detected. We conclude that real-time PCR is a sensitive and quantitative test for EHV-1 nasal shedding and viremia and provides a valuable tool for EHV-1 surveillance, diagnosis of clinical disease, and investigation of vaccine efficacy.
Introduction
Equine herpesvirus-1 (EHV-1) infection is common in young horses throughout the world, causing acute contagious respiratory disease, epidemic abortion, myeloencephalitis, and neonatal death. 19 Viral latency and reactivation are important features of EHV-1 epidemiology, allowing virus to persist in previously infected horses with the potential for subsequent reactivation, shedding, and infection of other susceptible horses, or abortion in the latently infected horse itself. 1 There is a clear need for specific, sensitive techniques that allow the rapid diagnosis of clinical disease, as well as surveillance of susceptible populations. In addition, in the case of experimental studies of vaccine efficacy, a critical parameter for measuring immunological control of EHV-1 infection is determination of the amount of virus present in nasal secretions or in blood (viremia). 1 A variety of techniques have been reported for the diagnosis of EHV-1. Conventional virus isolation uses cell cultures, with confirmation of viral identity by immunostaining or polymerase chain reaction (PCR) analysis. 10 It is possible to quantify viral load in nasal swabs collected in viral transport media, but such quantification is difficult in the blood (viremia). Immunohistochemistry and in situ hybridization are valuable for postmortem diagnosis. 7, 23, 24, 26 Conventional PCR is a sensitive technique for EHV diagnosis and can distinguish between EHV-1 and EHV-4 infection. 12, 20 When nested PCR is used it is possible to detect latent EHV infection. 4, 8 Recently a nested PCR-enzyme-linked immunosorbent assay (ELISA) system has also been described. 6 All of these techniques suffer from some disadvantages: virus isolation techniques are labor intensive and time consuming; immunohistochemistry and in situ hybridization have limited sensitivity; and conventional PCR and PCR-ELISA are not quantitative.
Real-time PCR technology is a flexible, rapid, sensitive, specific, and quantitative method for the diagnosis of infectious disease 13 and has been used for the diagnosis of herpesviral disease. 9 Real-time PCR has been successfully used in the horse for the detection of several infectious disease agents, including: Ehrlichia spp., 18 equine infectious anemia, 5 Salmonella spp., 11 Taylorella equigenitalis, 17 West Nile virus, 25 and equine arteritis virus. 3 This article describes the development and validation of a realtime PCR diagnostic assay for detection of EHV-1 in equine nasal and blood samples and compares the performance of this assay with viral isolation.
Materials and Methods

Experimental animals
Nineteen ponies between 1 and 2 years of age and of both sexes were used in this study. Ponies were housed in individual stalls in a semi-isolation unit, fed twice daily with a diet of hay and pelleted concentrate, and maintained according to the animal care guidelines of the Research Animal Resources Committee, University of Wisconsin-Madison, Wisconsin.
EHV-1 serology
All ponies were tested for serum neutralizing antibodies against EHV-1 at the Wisconsin Veterinary Diagnostic Laboratory, as described previously. 21 Known EHV-1 positive and negative sera were included as controls. Titers were expressed as the highest dilution of each sample that inhibited viral cytopathic effect and only seronegative ponies (titer less than 1:16) were entered into the study. The serum neutralization test was also performed on all ponies 28 days after experimental infections.
EHV-1 preparation and isolation
This experiment used EHV-1, strain Army 183 (EHV-1/ A183), donated by G. P. Allen (University of Kentucky, Lexington, KY). The virus was propagated in equine dermal cells (ATCC CCL-57), and cell-free virus-laden supernatant was used for experimental infections. In brief, to generate virus-containing supernatants, equine dermal cells were grown to 80% to 90% confluence in minimal essential media and infected with 50 ml of virus at a concentration of , 1 3 10 7 plaque-forming units (PFU)/ml. Flasks were placed in the incubator at 5% CO 2 , 37uC for 2 to 5 days at which point supernatants were collected and viral titers were determined after removal of cellular debris by centrifugation.
EHV-1 infection of ponies and sample collection
Experiment 1. Fifteen ponies were infected on day 0 by intranasal instillation of 2 3 10 7 PFU of EHV-1/A183 in a volume of 8 ml tissue culture supernatant, using a 5 1/4 inch 14-gauge IV catheter a placed into the ventral nasal meatus. Physical examinations were performed daily for 14 days postinfection (DPI). Rectal temperature, nasal discharge, and the occurrence of coughing were recorded. Nasal secretions were collected prior to infection on day 0 and daily for 10 DPI using 6-inch-long Dacron-tipped nasal swabs. b Swab tips were placed into vials containing 1 ml of viral transport medium (phosphate buffered saline [PBS] with 800 U/ml penicillin, 800 mG/ml streptomycin, 200 mG/ml gentamycin, 100 units/ml nystatin, and 5% glycerol) and stored at 280uC for use in both virus isolation and real-time PCR quantification of viral shedding. Blood was collected by jugular venipuncture into tubes containing heparin prior to EHV-1 infection on day 0, and daily for 10 DPI, and then every 2 days until 21 DPI, for detection of viremia by virus isolation. Blood was also collected into 5 ml EDTA prior to infection and every 2 days until 10 DPI for harvesting of buffy coat leukocytes for detection of viremia by real-time PCR. Experiment 2. Because EHV-1 DNA was not detected in buffy coat leukocytes by real-time PCR in experiment 1, a second study was conducted to determine if EHV-1 DNA could be detected in peripheral blood mononuclear cells (PBMCs) by real-time PCR. Three ponies were infected by intranasal administration of 4 3 10 7 PFU of EHV-1/A183, using the technique described above. An additional pony was not infected and served as a control. Physical examinations were performed daily for 11 DPI and on day 14 postinfection. Prior to infection, and on 1 to 10 DPI, 14 DPI, and 21 DPI, heparinized blood was collected for detection of viremia by virus isolation. Blood was collected on the same days for isolation of PBMCs for real-time PCR detection of viremia. For this purpose, blood was collected into sodium citrate anticoagulant in two 8-ml Cell Preparation Tubes, c which allow for separation of PBMCs by density gradient centrifugation.
In vitro infection of equine peripheral blood mononuclear cells with EHV-1
To produce high enough EHV-1 DNA copy numbers to generate a real-time PCR standard curve, equine PBMCs were infected in vitro as described previously. 2, 22 In brief, PBMCs were stimulated with pokeweed mitogen for 48 hr, and lymphoblasts were purified by density gradient separation prior to incubation with 10 PFU of EHV-1 per cell for 90 min. PBMCs were extensively washed prior to isolation of PBMC DNA as described below.
Probe and primer design for real-time PCR
The target sequence for real-time PCR was a region of the EHV-1 gB gene (GenBank accession no. M36298) that is sufficiently different from the EHV-4 gB gene (GenBank accession no. M26171) to achieve selective amplification of a 106 base pair sequence from only the EHV-1 gB gene. Forward and reverse PCR primers and a fluorogenic TaqMan probe were designed using Primer Express 1.5 d and manufactured by IDT Technologies (Coralville, IA). The sequence of the forward primer annealing to EHV-1 gB 1209 to 1230 was 59-CAT ACG TCC CTG TCC GAC AGA T-39. The sequence of the reverse primer annealing to EHV-1 gB 1314 to 1295 was 59-GGT ACT CGG CCT TTG ACG AA-39. The sequence of the 25 oligonucleotide probe annealing to EHV-1 gB 1275 to 1250 was 59-TGA GAC CGA AGA TCT CCT CCA CCG A-39, and included the 59 reporter dye 6-carboxyfluorescein (FAM) and 39 Black Hole Quencher dye. Primers and probe were diluted to 100 mM in RNase/DNase free sterile water, aliquoted, and stored at 220uC.
Preparation of plasmid for the standard curve
The sequence encoding the EHV-1 gB glycoprotein was cloned into the pRc/CMV plasmid e, 15 and amplified in Escherichia coli. Plasmid DNA was isolated using the Qiagen Maxiprep Kit f according to the manufacturer's recommendations. DNA concentration was determined using a Bio-Spec 1601 spectrophotometer g and plasmid copy number was calculated.
Real-time PCR protocol
For detection of viremia or of nasal EHV-1 shedding, DNA was extracted from 10 7 buffy coat leukocytes or PBMCs, or from 200 ml of nasal viral transport medium, respectively, using the High Pure PCR Template Preparation Kit h according to the manufacturer's directions. DNA concentrations were determined by spectrophotometry, and 0.1 mg of sample DNA (0.5 mg from PBMCs in experiment 2) was used in a total of 25 ml of PCR reaction mixture. Amplification and detection were performed using the Bio-Rad iCycler i under the following conditions: 3 min at 95uC, followed by 40 cycles of 30 sec at 95uC and then 30 sec at 60uC. All samples were run in triplicate, and all reactions included no-template controls. EHV-4 DNA o was used as negative control DNA, to determine the specificity of the assay. The sensitivity of the real-time PCR reaction was determined using a log dilution of the gB-containing plasmid that included from 6 to 6 3 10 8 total gB copies in each reaction. Amplification efficiencies were compared using the slopes of standard curves generated with DNA from the gBcontaining plasmid, DNA from nasal swab samples, and DNA prepared from PBMCs infected in vitro with EHV-1.
Virus isolation and quantification
Nasal viral shedding was quantified from viral transport medium in which the nasal swab tips had been immersed. The transport medium was passed through a 0.45-mm filter and added to 90% confluent cultures of equine dermal cells. Ten-fold dilutions were added to duplicate wells, and cultures were incubated at 37uC, 4% CO 2 for 1.5 hr. Inocula were then removed and plates were rinsed with minimal essential medium (MEM j ) plus 2% fetal calf serum. Methylcellulose medium (MEM containing 0.75% methyl cellulose, k 100 U/ml penicillin and 100 mg/ml streptomycin, NaHCO 3 [85 g/liter], amino acids, vitamins, glutamine, amphotericin B, j and 2% fetal calf serum l ) was added to each well, and the plates were incubated for 3 days at 37uC, 4% CO 2 . The medium was then removed and cells were stained with 1 ml of crystal violet m per well for 30 min. Plaques were counted and nasal viral shedding was quantified as PFU/ml of nasal swab sample.
For detection of viremia, 15 ml of blood was collected into heparin, and red blood cells were allowed to settle. The leukocyte-rich plasma was collected and leukocytes were pelleted, washed 3 times in PBS, and subsequently resuspended in 10 ml of MEM plus 2% fetal calf serum, before addition to 25-cm 2 tissue culture flasks n containing 90% confluent monolayers of equine dermal cells. Flasks were incubated for 7 days at 37uC, 4% CO 2 , and checked daily for appearance of cytopathic effect (CPE). After 7 days, the virus containing supernatants from CPEpositive flasks were recovered by freeze-thawing, and 500ml aliquots were added to new 25-cm 2 tissue culture flasks containing 90% confluent monolayers of equine dermal cells. These second-pass flasks were incubated for a further 7 days at 37uC, 4% CO 2 , and the appearance of CPE was recorded as a positive result. A sample was determined to be positive for viremia when CPE was evident in the second passage in cell culture. We have previously confirmed using PCR that CPE after the second pass is always associated with the presence of EHV-1.
Detection of latent EHV-1 infection in ponies
To determine if ponies were latently infected with EHV-1 prior to experimental infection, 1 3 10 7 PBMCs were collected from each of the 15 ponies used in experiment 1, and DNA was isolated using the High Pure PCR Template Preparation Kit. h Latent infection prior to the experimental challenge infection was identified using nested PCR, as described previously. 4 This PCR used 2 primer pairs specific for the EHV-1 gB gene. To determine whether the real-time PCR reaction would detect latent infections, these assays were run using 0.5 mg of sample DNA isolated from PBMCs from these 15 ponies prior to experimental infection in addition to negative and positive control DNA.
Results
Sensitivity and specificity of the real-time PCR assay
The analytical sensitivity of the real-time PCR assay was determined from a dilution series of EHV-1 gB DNA isolated from the pRc/CMV plasmid. The highest concentration of plasmid was calculated to contain 6 3 10 8 copies of the EHV-1 gB gene. Serial log dilutions of this starting material were performed, and the lowest limit of the assay was a 1 3 10 28 dilution (Fig. 1 ). Therefore the assay was able to detect as few as 6 copies of the plasmid-derived EHV-1 gB gene.
As described above, the primers and probe were designed to distinguish the gB sequence of EHV-1 from that of EHV-4. Alignment of the primer and probe sequences with the complete EHV-4 and EHV-2 genome sequences failed under nonstringent conditions using Seqman II software. p EHV-4 DNA was used as negative control template DNA in all experiments, and in all instances there was no evidence of nonspecific amplification products from EHV-4 DNA, from no-template controls, or from any other biological samples not expected to contain EHV-1 DNA, specifically the preinfection PBMCs and nasal swab samples.
Standard curve and dynamic range of the real-time PCR assay
Amplification of the log dilution series obtained from the plasmid-derived EHV-1 gB DNA showed linearity over a dynamic range of 8 log 10 dilutions. A typical data series is shown in Fig. 1 , with a correlation coefficient (R 2 ) of 0.9963. Amplification efficiency was calculated from the equation: efficiency 5 10 1/2s 2 1, where s 5 slope. An efficiency of 1, or 100%, represents a slope of 3.32. For the EHV-1 gB plasmid DNA, the amplification efficiency was 105% ( Fig. 1 ). No assay data was used if the efficiency of the reaction with the plasmid standard was not equal to 100% 6 5 %.
The real-time PCR assay was able to detect EHV-1 DNA prepared from PBMCs isolated from experimentally infected ponies (see section -''Detection of viremia after EHV-1 infection''); however, the copy number was not high enough to generate a standard curve with more than 2 log 10 dilutions of the starting material. Figure 1 depicts the standard curve that was therefore generated from DNA prepared from equine PBMCs that were infected with EHV-1 in vitro, as well as a standard curve generated from DNA isolated from nasal secretions from EHV-1-infected horses. The standard curve from the PBMC-derived DNA showed linearity over a range of 5 log 10 dilutions with an R 2 of 0.9993, and the DNA from nasal secretions gave a curve with linearity over a range of 3 log 10 dilutions with an R 2 of 0.9828. The efficiencies were 97.6% for PBMC-derived EHV-1 DNA, and 104% for EHV-1 DNA isolated from nasal secretions (Fig. 1 ).
Detection of virus in nasal secretions after EHV-1 infection
Subsequent to experiment 1, virus isolation detected nasal shedding in 12 of the 15 ponies, on a total of 24 days postinfection (Fig. 2) . The number of days on which viral shedding was detected in individual ponies ranged from 1 to 4, with a mean of 2 days of detectable viral shedding for each pony by virus isolation. In contrast, real-time PCR detected nasal viral shedding in all 15 ponies, over a total of 74 days postinfection, with a mean of 4.9 days per pony, and a range of 2 to 7 days (Fig. 2) . Both viral isolation and real-time PCR demonstrated that shedding of EHV-1 in nasal secretions begins as soon as 1 day after experimental infection. Virus isolation detected viral shedding up to 4 DPI, while real-time PCR detected viral shedding up to 7 DPI. Neither real-time PCR nor virus isolation demonstrated shedding of EHV-1 in nasal secretions obtained preinfection (day 0), and neither technique demonstrated nasal viral shedding beyond 7 DPI (Fig. 2) . In no instance was a pony positive for nasal viral shedding by virus isolation without also being positive on real-time PCR.
Clinical signs of EHV-1 infection included pyrexia (rectal temperature . 101.5uF) from 1 to 8 DPI, and mucopurulent nasal discharge from 1 to 18 DPI; no coughing was detected. When mean temperature was compared with nasal viral shedding (Fig. 3) , the pyrexia was shown to be biphasic, peaking on days 1 and 6 postinfection. Peak nasal viral shedding coincided with the first pyrexia peak. All ponies seroconverted to EHV-1, with titers ranging from 1:64 to 1:512 by 28 DPI.
Detection of viremia after EHV-1 infection
EHV-1 DNA was not detected by real-time PCR in buffy coat leukocytes obtained from the 15 infected ponies in experiment 1. Virus isolation detected viremia in 9 ponies between days 3 and 16 DPI, with a duration ranging from 1 to 3 days. The yield and quality of DNA prepared from whole leukocyte populations in this experiment were judged to be poor based on spectrophotometric analysis and agarose gels, and therefore a second study (experiment 2) was conducted to determine if EHV-1 could be detected by real-time PCR from a larger amount (0.5 mg) of DNA prepared from PBMCs isolated from experimentally infected ponies.
In experiment 2, the real-time PCR assay detected EHV-1 DNA from PBMCs isolated from 3 of the 3 ponies that were experimentally infected (Fig. 4 ), but The clinical signs seen in experiment 2 were similar to those in experiment 1, with biphasic pyrexia, peaking on days 1 and 6, with the onset of viremia coinciding with the second pyrexia peak. All 3 infected ponies developed mucopurulent nasal discharge, and seroconverted to EHV-1 with titers ranging from 1 : 128 to 1 : 512 by 28 DPI.
Detection of latent EHV-1 infection in ponies
Prior to experiment 1, when DNA was isolated from PBMCs from the 15 ponies and analyzed by both nested PCR and by real-time PCR, the nested PCR demonstrated that 11 of the 15 ponies were positive for latent EHV-1 infection. In contrast, the same samples tested negative for EHV-1 DNA using the real-time PCR assay, using 0.5 mg of sample DNA for each assay.
Discussion
This study demonstrates that real-time PCR is a sensitive and specific assay for the detection of Figure 2 . Results of EHV-1 detection in nasal samples by conventional viral isolation or by real-time PCR detection of gB DNA are shown for 15 individual ponies in experiment 1. Ponies were infected on day 0 and studied for 10 days; data are only shown for 8 days as no virus was detected by either method beyond day 7. Results for real-time PCR gB (log 10 ) copy number in 100 ng of sample DNA are plotted as a continuous line, and results for conventional virus isolation (log 10 ) PFU/ml viral transport medium are plotted as bars.
EHV-1 gB DNA in both nasal secretions and blood samples from experimentally infected ponies. The results indicate that real-time PCR has several advantages over virus isolation, including higher sensitivity, a simpler means of quantifying viral DNA, and a shorter time for completion of assays. Additional advantages are that real-time PCR technology is widely available and relatively economical. Therefore, this assay will be easier to establish and maintain in a diagnostic or research laboratory, compared with viral isolation and characterization.
The gB gene was selected for identification of a target amplicon because several independently derived sequences for this gene in GenBank demonstrated no evidence of variability amongst EHV-1 isolates. In addition, a well-characterized plasmid encoding the gB gene was available for validation and generation of standard curves. The sensitivity of the test was demonstrated by the detection of as few as 6 copies of the gB gene in all assays performed. Consistent assay performance was obtained across 8 log 10 concentrations of the plasmid control, and across all possible dilution series of DNA isolated from nasal secretions from infected horses, or in vitro infected PBMCs. The specificity of the test was demonstrated by the use of DNA from EHV-4, the closest relative of EHV-1, as a negative control in all assays.
The real-time PCR assay for EHV-1 demonstrated no false negative results, in that all samples that were positive on virus isolation were also positive by realtime PCR. There were numerous instances in which real-time PCR identified gB DNA in samples that were negative by virus isolation. The ability to detect virus more frequently with real-time PCR could result from the ability of the real-time PCR assay to detect fewer virions than the minimum number required to initiate a productive infection in cell culture. It is also possible that the real-time PCR assay detects noninfectious virus. However, positive real-time PCR detection of gB DNA only occurred following a recent experimental infection. There was therefore no indication that these were false positive results. The results of real-time PCR measurement of gB DNA copy number in both nasal samples and in blood samples are consistent with the onset of infection, peak viral shedding and viremia, and resolution of infection. In addition, the real-time PCR test was negative prior to infection in several animals that were diagnosed as latently infected based on nested PCR. Therefore, on the basis of this study, the realtime PCR test detects active nasal viral shedding or viremia but is not sensitive enough to detect latent infection. This characteristic of the real-time PCR test has utility for the diagnosis of EHV-1 infection in horses, as positive real-time PCR results indicate active, and therefore clinically significant and potentially contagious, infection. Confidence in this interpretation could be further increased by taking the additional conservative step of only accepting positive results when they are 1 log greater than the minimal sensitivity reported in this study. Even in these circumstances, the real-time PCR test continues to outperform conventional isolation in virus detection.
Because real-time PCR provides quantitative results, this methodology can readily be applied to the measurement of viral load and the evaluation of viral shedding. 14, 16 The ability to easily quantify viral load may be valuable in a number of contexts, for example, in the evaluation of vaccination efficacy. It has been proposed that the ability to limit the extent of viremia is likely to be critical for the control of the occurrence of EHV-1 abortion or myelitis. 1 The utility of the real-time PCR assay for quantifying viremia far outperforms the ability of any alternative assay system for this purpose, and real-time PCR may be the assay of choice for measuring this parameter. One limitation of our comparison of real-time PCR and conventional virus isolation for detecting viremia is that we used PBMCs for the real-time PCR tests, and buffy coat leukocytes for the conventional virus isolation. While conventional virus isolation results are generally similar whether leukocytes or PBMCs are used, it remains possible that we might have obtained different results with PBMCs in this application.
In the present experiments, quantification of the amount of viral DNA was based on loading a fixed amount of sample DNA into the PCR reaction, and comparing results to a standard curve. An alternative approach would be to report the viral DNA copies detected in reference to a reporter or housekeeping gene. For nasal secretions, there was no clear housekeeping gene candidate. For blood samples, there are clearly several possible candidates, and the assay might be refined by the use of such a system. One alternative enhancement of this quantitative assay would be to add a source of DNA containing a known target sequence to all samples prior to sample processing and extraction and use its detection to control for nucleic acid isolation and amplification efficiencies. 16 Nevertheless, in the present study the use of an external plasmid standard and loading a standard amount of sample DNA identified a pattern of viral shedding in these highly controlled infection experiments that was entirely consistent with all expectations of EHV-1 infection, validating the utility of this approach. In addition, measurement of DNA concentration is simple and economical, whereas detection of an additional gene would significantly increase the cost and complexity of the assay.
Although the sensitivity of the real-time PCR assay led to detection of as few as 6 copies per reaction, we experienced poor test performance using leukocyte DNA, compared with PBMC DNA, indicating poor sample quality. The detection of viremia by real-time PCR assay could have been simplified, and therefore improved, if DNA had been successfully prepared from whole blood, rather than separated PBMC preparations. The test might therefore be further enhanced if similar results could be generated using a simplified blood DNA purification protocol.
The need for high quality diagnostic tests for EHV-1 arises from the frequent occurrence of EHV-1mediated disease in horses, and the fact that there are numerous differential diagnoses for its many manifestations. The real-time PCR methodology requires that samples be submitted to a laboratory for analysis and is unlikely to lead to a stall-side test. However, within a laboratory, the real-time PCR test provides the many advantages described above. Virus isolation remains necessary for studies of genetic variation with EHV-1 isolates, and identification of variants associated with higher pathogenicity. However, the potential for rapid diagnosis, high throughput, and the sensitivity and quantitative nature of the real-time PCR test all make it highly suitable to replace virus isolation for both surveillance and diagnostic and research purposes.
